Emerging within the medical landscape, retatrutide signifies a potential development in obesity management space. This innovative dual agonist targeting both GLP-1 and GIP receptors demonstrates substantial efficacy in clinical trials , implying a enhanced ability to encourage weight reduction and address associated health concerns. While currently